Compass points to strong psilocybin data in depression

Why Did Compass Pathways Stock Rocket Higher Today?

Key PointsPhase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome.Results included maintaining a generally well-tolerated and safe profile.10 stocks we like better than Compass Pathways Plc › It's been a long road for Compass Pathways (NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) c…

Compass points to strong psilocybin data in depression

Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.

Compass says its psilocybin drug helped patients with severe depression in two trials

The treatment, called COMP360, is intended to treat severe depression. It could be the first psilocybin-based medicine on the market.

Compass Pathways clears second phase III hurdle for psilocybin in treatment-resistant depression - European Biotechnology Magazine

The share price of London-based Compass Pathways soared over 30% on Tuesday after the company reported that its synthetic psilocybin formulation COMP360 had met the primary endpoint in the second of two pivotal phase III trials in treatment-resistant depression (TRD), confirming consistent results across 839 patients and clearing the path toward what would be the first regulatory filing of a classic psychedelic for a psychiatric indication. The …

Compass Pathways Phase 3 Psilocybin Results & FDA Approval Timeline

Compass Pathways has reported positive results from its second large-scale Phase 3 trial of COMP360, a synthetic psilocybin treatment for treatment-resistant depression (TRD). The study demonstrated that a high dose of the compound led to a statistically significant and clinically meaningful reduction in depression symptoms compared to a control group, with effects appearing as early as the day after administration. Following these results, the …

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals

The second pivotal trial of Compass Pathways’ psilocybin formulation for treatment-resistant depression has succeeded, the company said Tuesday, a result that could help the drug gain approval next year. The first approval trial of the ...